# HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

> **NCT05751850** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 778 (estimated)

## Conditions studied

- First-line Treatment of Advanced Pancreatic Cancer

## Interventions

- **DRUG:** HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
- **DRUG:** nab-paclitaxel; gemcitabine

## Key facts

- **NCT ID:** NCT05751850
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 778 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751850, "HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05751850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*